XML 78 R58.htm IDEA: XBRL DOCUMENT
v3.23.3

COMMITMENTS (Narrative) (Details) - License Agreement [Member] - Technology-based intangible assets | 12 Months Ended
--- | ---
Sep. 30, 2023 CAD ($)
Other Commitments [Line Items] |
Minimum advance royalty payments | $ 85,000
Milestone payment to be paid upon filing an Investigational New Drug (IND) Application. | 20,000
Milestone payment to be made at the start of a Phase II clinical trial | 50,000
Milestone payment to be made at the start of a Phase III clinical trial | 900,000
Milestone payment to be made at application for marketing approval, and with further milestone payments on the second and additional compounds | 1,450,000
Amount of milestone payment made for filing an Investigational New Drug (IND) Application. | $ 20,000

X
- Definition The amount of milestone payments made for filing the Investigational New Drug (IND) Application. + References No definition available. + Details
Name: | epix_AmountOfMilestonePaymentForFilingOfApplication
Namespace Prefix: | epix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payments made at application for marketing approval and with further milestone payments on the second and additional compounds. + References No definition available. + Details
Name: | epix_AmountOfMilestonePaymentsAtApplicationForMarketingApproval
Namespace Prefix: | epix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payment to be made at the start of the Phase II clinical trial. + References No definition available. + Details
Name: | epix_AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial
Namespace Prefix: | epix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payments to be made at the start of a Phase III clinical trial. + References No definition available. + Details
Name: | epix_AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial
Namespace Prefix: | epix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payments to be paid upon filing an Investigational New Drug (IND) Application. + References No definition available. + Details
Name: | epix_AmountOfMilestoneToBePaidForFilingOfApplication
Namespace Prefix: | epix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition It represents amount of minimum annual royalty payments per annum. + References No definition available. + Details
Name: | epix_MinimumAdvanceRoyaltyPayments
Namespace Prefix: | epix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=epix_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |